Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

Expert consensus on relevant risk predictors for the occurrence of osteoporotic fractures in specific clinical subgroups - Delphi survey.

Bodmer NS, Häuselmann HJ, Frey D, Aeberli D, Bachmann LM.

BMC Rheumatol. 2019 Nov 12;3:50. doi: 10.1186/s41927-019-0099-y. eCollection 2019.

2.

Follow-Up of Bone Mineral Density Changes in de novo Kidney Transplant Recipients Treated with Two Doses of the Receptor Activator of Nuclear Factor κB Ligand Inhibitor Denosumab.

Kobel C, Frey D, Graf N, Wüthrich RP, Bonani M.

Kidney Blood Press Res. 2019;44(5):1285-1293. doi: 10.1159/000503066. Epub 2019 Oct 15.

3.

Relationship of Serum Bicarbonate Levels with 1-Year Graft Function in Kidney Transplant Recipients in Switzerland.

Wiegand A, Graf N, Bonani M, Frey D, Wüthrich RP, Mohebbi N.

Kidney Blood Press Res. 2019;44(5):1179-1188. doi: 10.1159/000502527. Epub 2019 Sep 19.

4.

[From Axial Spondyloarthritis to Osteoporosis - Spectrum of Skeletal Involvement in Inflammatory Bowel Diseases].

Schüle S, Frey D, Biedermann L, Grueber MM, Zeitz J, Vavricka S, Möller B, Rogler G, Misselwitz B.

Praxis (Bern 1994). 2019 Sep;108(12):799-806. doi: 10.1024/1661-8157/a003301. German.

PMID:
31530124
5.

Effect of denosumab on trabecular bone score in de novo kidney transplant recipients.

Bonani M, Frey D, Graf N, Wüthrich RP.

Nephrol Dial Transplant. 2019 Oct 1;34(10):1773-1780. doi: 10.1093/ndt/gfy411.

PMID:
30932161
6.

Single-level vertebral kyphoplasty is not associated with an increased risk of symptomatic secondary adjacent osteoporotic vertebral compression fractures: a matched case-control analysis.

Teuber H, Tiziani S, Halvachizadeh S, Frey D, Sprengel K, Pape HC, Osterhoff G.

Arch Osteoporos. 2018 Jul 27;13(1):82. doi: 10.1007/s11657-018-0489-6.

PMID:
30054751
7.

Food intake and energy expenditure in growing cats with and without a predisposition to overweight.

Ghielmetti V, Wichert B, Rüegg S, Frey D, Liesegang A.

J Anim Physiol Anim Nutr (Berl). 2018 Oct;102(5):1401-1410. doi: 10.1111/jpn.12928. Epub 2018 Jun 19.

PMID:
29920783
8.

Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO.

Meier C, Uebelhart B, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Frey D, Kressig RW, Lamy O, Lippuner K, Stute P, Suhm N, Ferrari S.

Swiss Med Wkly. 2017 Aug 16;147:w14484. doi: 10.4414/smw.2017.14484. eCollection 2017.

9.

Normative values for CT-based texture analysis of vertebral bodies in dual X-ray absorptiometry-confirmed, normally mineralized subjects.

Mannil M, Eberhard M, Becker AS, Schönenberg D, Osterhoff G, Frey DP, Konukoglu E, Alkadhi H, Guggenberger R.

Skeletal Radiol. 2017 Nov;46(11):1541-1551. doi: 10.1007/s00256-017-2728-0. Epub 2017 Aug 6.

PMID:
28780746
10.

Osteoporosetherapie : Facts und Fragen.

Frey D.

Rev Med Suisse. 2017 Jan 25;13(547):223-224. German. No abstract available.

PMID:
28703984
11.

Metabolic response to three different diets in lean cats and cats predisposed to overweight.

Keller C, Liesegang A, Frey D, Wichert B.

BMC Vet Res. 2017 Jun 19;13(1):184. doi: 10.1186/s12917-017-1107-3.

12.

Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.

Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Kuntzen T, Greuter T, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study.

Medicine (Baltimore). 2017 Jun;96(22):e6788. doi: 10.1097/MD.0000000000006788.

13.

Infections in De Novo Kidney Transplant Recipients Treated With the RANKL Inhibitor Denosumab.

Bonani M, Frey D, de Rougemont O, Mueller NJ, Mueller TF, Graf N, Wüthrich RP.

Transplantation. 2017 Sep;101(9):2139-2145. doi: 10.1097/TP.0000000000001547.

14.

Effect of Denosumab on Peripheral Compartmental Bone Density, Microarchitecture and Estimated Bone Strength in De Novo Kidney Transplant Recipients.

Bonani M, Meyer U, Frey D, Graf N, Bischoff-Ferrari HA, Wüthrich RP.

Kidney Blood Press Res. 2016;41(5):614-622. Epub 2016 Sep 14.

15.

Safety and efficacy of extracorporeal shock wave therapy (ESWT) in calcinosis cutis associated with systemic sclerosis.

Blumhardt S, Frey DP, Toniolo M, Alkadhi H, Held U, Distler O.

Clin Exp Rheumatol. 2016 Sep-Oct;34 Suppl 100(5):177-180. Epub 2016 Aug 3.

PMID:
27494629
16.

Prediction of low bone mineral density in patients with inflammatory bowel diseases.

Schüle S, Rossel JB, Frey D, Biedermann L, Scharl M, Zeitz J, Freitas-Queiroz N, Pittet V, Vavricka SR, Rogler G, Misselwitz B; Swiss IBD cohort study.

United European Gastroenterol J. 2016 Oct;4(5):669-676. Epub 2016 Jun 30.

17.

Sclerostin blood levels before and after kidney transplantation.

Bonani M, Rodriguez D, Fehr T, Mohebbi N, Brockmann J, Blum M, Graf N, Frey D, Wüthrich RP.

Kidney Blood Press Res. 2014;39(4):230-9. doi: 10.1159/000355781. Epub 2014 Jul 31.

18.

Randomized clinical trial evaluating transdermal Ibuprofen for moderate to severe knee osteoarthritis.

Varadi G, Zhu Z, Blattler T, Hosle M, Loher A, Pokorny R, Frey D, Carter SG.

Pain Physician. 2013 Nov-Dec;16(6):E749-62.

19.

Streptococcus pyogenes upper respiratory infection and atopic conditions other than asthma: a retrospective cohort study.

Juhn YJ, Frey D, Li X, Jacobson R.

Prim Care Respir J. 2012 Jun;21(2):153-8. doi: 10.4104/pcrj.2011.00110.

20.

Assessment of the association between pediatric asthma and Streptococcus pyogenes upper respiratory infection.

Frey D, Jacobson R, Poland G, Li X, Juhn Y.

Allergy Asthma Proc. 2009 Sep-Oct;30(5):540-5. doi: 10.2500/aap.2009.30.3268. Epub 2009 Aug 11.

PMID:
19674512

Supplemental Content

Loading ...
Support Center